General Information of Drug (ID: DM09TVB)

Drug Name
Zimura Drug Info
Synonyms ARC-1905
Indication
Disease Entry ICD 11 Status REF
Macular degeneration 9B78.3 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM09TVB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Complement C5 (CO5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ravulizumab DMSWNJF Paroxysmal nocturnal haemoglobinuria 3A21.0 Approved [3]
Zilucoplan DM9Z4N5 Generalized myasthenia gravis 8C60 Approved [4]
Pozelimab DMTE8DC Large B Cell Lymphoma Approved [5]
Avacincaptad pegol DM1Z3Z2 Geographic atrophy 9B75 Approved [6]
SKY59 DMWOF1E Haemolytic uraemic syndrome 3A21.2 Phase 3 [7]
SB12 DMME6GJ Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [8]
ABP959 DMDXE4I Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [9]
Coversin DMMEAOL Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [10]
Nomacopan DML6E6G Bullous pemphigoid EB41.0 Phase 3 [11]
ALXN1720 DMOB3CI Generalized myasthenia gravis 8C60 Phase 3 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04435366) A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor). U.S. National Institutes of Health.
2 C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.
6 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217225
7 The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920.
8 Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729.
9 A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris ?) in healthy male subjects. Eur J Haematol. 2020 Jul;105(1):66-74.
10 Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258.
11 Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol. 2022 Jun 1;158(6):641-649.
12 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight